

06-13-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Herpin, et al

Application No.: 10/009,621

Filed: 6/13/2000

Title: **SOLID PHASE SYNTHESIS OF N,N-
DISUBSTITUTED
DIAZACYCLOALKYLCARBOXY
DERIVATIVES**



Examiner:

Art Unit:

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

6/11/2002

Date of Deposit

Signature

EV 069261853 US

Express Mail No.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A list of relevant references appear on the attached PTO-1449 form.


Respectfully submitted,


George G. Wang, Reg. No. 41,419
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2843
Telefax (908) 231-2626

Docket No. A3321 US PCT

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. A3321 US PCT	SERIAL NO. 10/009,621
	APPLICANT Herpin, et al	
	FILING DATE 6/13/2000	GROUP



U.S. PATENT DOCUMENTS

EXAMINER INITIALS			DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE
<i>DK</i>		A.1	5	8	8	0	1	2	8	3/9/1999	Doll, et al			
<i>DK</i>		A.2	5	7	3	4	0	5	4	3/31/1998	Dolle, III			
<i>DK</i>		A.3	5	3	2	4	4	8	3	6/28/1994	Cody, et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS			DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION YES NO
<i>DK</i>		B.1	9	8	5	8	9	4	7	6/5/1998	WO			

OTHER DOCUMENTS

EXAMINER INITIALS			AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.											
<i>DK</i>		C.1	GENERATION OF A PIPERAZINE-2-CARBOXAMIDE LIBRARY: A PRACTICAL APPLICATION OF THE PHENOL-SULFIDE REACT AND RELEASE LINKER; Breitenbucher et al, Tet. Lett, 3/12/1998, Vol. 39, pp. 1295-1298											
<i>DK</i>		C.2	EVALUATION OF A STRUCTURE-BASED STATINE CYCLIC DIAMINO AMIDE ENCODED COMBINATORIAL LIBRARY AGAINST PLASMEPSIN ii AND CATHEPSIN D; Carroll et al, Bioorganic & Medicinal Chem Lett 8, (1998), pp. 3203-3206											

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Note: Asterisk (*) item(s) have been previously cited in a related application(s) either by the applicant or by the USPTO and therefore copies of the reference(s) are not being submitted